In the present subsection, GRP75 (HSPA9 or mortalin) is considered as a molecular target for inducing the complement-dependent cytotoxicity toward breast cancer cells [231,249] and also for antibody-mediated delivery of the mortalin inhibitor CAPE into breast cancer cells [250]. This evidence concerns the gene SMC2 and breast cancer.